YU99603A - Geni koji su povezani sa virulencijom parazita laišmanije - Google Patents
Geni koji su povezani sa virulencijom parazita laišmanijeInfo
- Publication number
- YU99603A YU99603A YU99603A YUP99603A YU99603A YU 99603 A YU99603 A YU 99603A YU 99603 A YU99603 A YU 99603A YU P99603 A YUP99603 A YU P99603A YU 99603 A YU99603 A YU 99603A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- protein
- cys
- lmpdi
- leishmania
- gene associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Pronalazak je iz oblasti suzbijanja lajšmanioze. Pomenuti pronalazak se bavi izolovanjem, iz divljih izolata Leishmania major, proteina i kodirajućeg gena poznatog kal LmPDI, koji ima dva regiona koji su identični sekvenci (Cys-Gly-His-Cys) potencijalnog aktivnog mesta protein disulfid-izomere (PDI). LmPDI je predominantno eksprimiran u najvirulentnijim izolatima parazita. Pomenuti protein prvenstveno formira novu terapeutsku metu za razvijanje lekova protiv Lašmanije, a kao drugo to je novi element koji ulazi u sastav imunogenih preparata i preparata za vakcinaciju ljudi ili životinja domaćina protiv lajšmanioze.[The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein- coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His- Cys) of the potential active site of the protein disulphide isomerases (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0107985A FR2826018B1 (fr) | 2001-06-18 | 2001-06-18 | Gene associe a la virulence du parasite leishmania |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU99603A true YU99603A (sh) | 2006-05-25 |
Family
ID=8864458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU99603A YU99603A (sh) | 2001-06-18 | 2002-06-17 | Geni koji su povezani sa virulencijom parazita laišmanije |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1414967B1 (sh) |
| JP (2) | JP2004537299A (sh) |
| KR (1) | KR20040023621A (sh) |
| CN (2) | CN1526017A (sh) |
| AU (2) | AU2002345672B2 (sh) |
| BR (1) | BR0210486A (sh) |
| CZ (1) | CZ20033430A3 (sh) |
| FR (1) | FR2826018B1 (sh) |
| HR (1) | HRP20031046A2 (sh) |
| HU (1) | HUP0400204A3 (sh) |
| MX (1) | MXPA03011904A (sh) |
| NZ (1) | NZ530459A (sh) |
| PL (1) | PL367113A1 (sh) |
| WO (1) | WO2002103002A2 (sh) |
| YU (1) | YU99603A (sh) |
| ZA (1) | ZA200309739B (sh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2540736A1 (en) * | 2005-04-08 | 2006-10-08 | Institut Pasteur | Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof |
| US20070015803A1 (en) * | 2005-04-12 | 2007-01-18 | Romark Laboratories L.C. | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| EP2141248B1 (en) * | 2008-07-03 | 2012-12-12 | Institut Pasteur | Methods to identify leishmania virulence factors |
| SA110310855B1 (ar) * | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
| AR083829A1 (es) * | 2010-11-10 | 2013-03-27 | Leti S L Unipersonal Lab | Coadyuvante con potencialidad inmunogenica incrementada |
| CN106085995B (zh) * | 2016-06-15 | 2019-07-12 | 华南理工大学 | 一种基因定点改造的蛋白质二硫键异构酶及其应用 |
| WO2018175346A1 (en) * | 2017-03-20 | 2018-09-27 | Spectral Platforms, Inc. | Spectroscopic methods to detect and characterize microorganisms |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2105538C (en) * | 1993-09-03 | 1999-03-09 | Gregory Matlashewski | Differentially expressed leishmania genes and proteins |
-
2001
- 2001-06-18 FR FR0107985A patent/FR2826018B1/fr not_active Expired - Fee Related
-
2002
- 2002-06-17 AU AU2002345672A patent/AU2002345672B2/en not_active Ceased
- 2002-06-17 CZ CZ20033430A patent/CZ20033430A3/cs unknown
- 2002-06-17 WO PCT/FR2002/002086 patent/WO2002103002A2/fr active Application Filing
- 2002-06-17 EP EP02751257.3A patent/EP1414967B1/fr not_active Expired - Lifetime
- 2002-06-17 KR KR10-2003-7016587A patent/KR20040023621A/ko not_active Application Discontinuation
- 2002-06-17 PL PL02367113A patent/PL367113A1/xx not_active IP Right Cessation
- 2002-06-17 BR BR0210486-5A patent/BR0210486A/pt not_active Withdrawn
- 2002-06-17 MX MXPA03011904A patent/MXPA03011904A/es not_active Application Discontinuation
- 2002-06-17 JP JP2003506456A patent/JP2004537299A/ja active Pending
- 2002-06-17 CN CNA02813849XA patent/CN1526017A/zh active Pending
- 2002-06-17 CN CNA2008100013487A patent/CN101274960A/zh active Pending
- 2002-06-17 HU HU0400204A patent/HUP0400204A3/hu unknown
- 2002-06-17 YU YU99603A patent/YU99603A/sh unknown
- 2002-06-17 NZ NZ530459A patent/NZ530459A/en not_active Application Discontinuation
-
2003
- 2003-12-17 ZA ZA200309739A patent/ZA200309739B/xx unknown
- 2003-12-17 HR HR20031046A patent/HRP20031046A2/xx not_active Application Discontinuation
-
2008
- 2008-08-13 AU AU2008203830A patent/AU2008203830A1/en not_active Ceased
-
2009
- 2009-08-06 JP JP2009183479A patent/JP2009254386A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03011904A (es) | 2005-07-01 |
| FR2826018B1 (fr) | 2005-01-07 |
| PL367113A1 (en) | 2005-02-21 |
| HRP20031046A2 (en) | 2004-04-30 |
| NZ530459A (en) | 2008-04-30 |
| FR2826018A1 (fr) | 2002-12-20 |
| CZ20033430A3 (cs) | 2004-05-12 |
| CN101274960A (zh) | 2008-10-01 |
| CN1526017A (zh) | 2004-09-01 |
| JP2009254386A (ja) | 2009-11-05 |
| BR0210486A (pt) | 2004-08-17 |
| KR20040023621A (ko) | 2004-03-18 |
| HUP0400204A3 (en) | 2010-01-28 |
| ZA200309739B (en) | 2004-10-12 |
| JP2004537299A (ja) | 2004-12-16 |
| EP1414967A2 (fr) | 2004-05-06 |
| AU2008203830A1 (en) | 2008-09-11 |
| AU2002345672B2 (en) | 2008-05-29 |
| EP1414967B1 (fr) | 2015-04-15 |
| WO2002103002A2 (fr) | 2002-12-27 |
| WO2002103002A3 (fr) | 2004-02-26 |
| HUP0400204A2 (hu) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hotez et al. | Advancing a vaccine to prevent hookworm disease and anemia | |
| Martinez-Campos et al. | Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| BR0107972A (pt) | Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano | |
| Marques-da-Silva et al. | Intramuscular immunization with p36 (LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge | |
| HUP0400445A2 (hu) | Új vakcinakészítmények | |
| NO20045521L (no) | Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer | |
| HUP0400313A2 (hu) | Új, biotechnológiai úton előállított, humán terápiára alkalmas szuperantigének | |
| WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
| WO2002072036A3 (en) | Compositions and methods comprising west nile virus polypeptides | |
| HUP0401606A2 (hu) | West Nile vakcina | |
| Pacífico et al. | Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine | |
| WO2023094713A3 (en) | Coronavirus vaccine | |
| DK2011510T3 (da) | Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter | |
| Santos et al. | Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine | |
| Sansri et al. | Protection against Fasciola gigantica infection in mice by vaccination with recombinant juvenile-specific cathepsin L | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| DK1471936T3 (da) | HIV-Vaccine og fremgangsmåde til anvendelse | |
| BR0010155A (pt) | Proteìnas isolada, e quimérica, composição, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição de vacina recombinante ou composição de vacina atenuada, composição farmacêutica, métodos de imunizar um indivìduo contra um imunógeno, proteìna não-cd80 isolada, molécula de ácido nucleico, e, método de imunossuprimir um indivìduo | |
| YU99603A (sh) | Geni koji su povezani sa virulencijom parazita laišmanije | |
| Singh et al. | Covid-19 vaccines and community immunity | |
| BR112023021654A2 (pt) | Vacina contra vírus | |
| WO2004037175A3 (en) | Compositions and methods for treating human papillomavirus-mediated disease | |
| Carneiro et al. | Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis |